Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
52-week range
$81.74 – $112.58
93% from low
Exchange
NASDAQ
ETF
Borrow rate
3.74%
Moderate
No company description on file.
No one on the platform currently holds PPH.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 9,300 | $959.5K |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-01 | $0.8441 | 2026-04-07 |
| 2025-12-29 | $0.3106 | 2025-12-31 |
| 2025-10-01 | $0.3931 | 2025-10-06 |
| 2025-07-01 | $0.6069 | 2025-07-07 |
| 2025-04-01 | $0.5245 | 2025-04-04 |
| 2024-12-27 | $0.4110 | 2024-12-30 |
| 2024-10-01 | $0.4090 | 2024-10-04 |
| 2024-07-01 | $0.3558 | 2024-07-05 |
| 2024-04-01 | $0.5328 | 2024-04-05 |
| 2023-12-27 | $0.3074 | 2023-12-29 |
No one on the platform has traded PPH yet.
| -0.14% |
| $656M |
| — |
| FYCFirst Trust Small Cap Growth AlphaDEX Fund | $125.75 | +1.36% | $1.3B | — |
| IHEiShares U.S. Pharmaceuticals ETF | $100.13 | +1.01% | $776M | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2023-10-02 |
| $0.3398 |
| 2023-10-06 |
| 2023-07-03 | $0.3891 | 2023-07-07 |
| Execution date | Ratio |
|---|---|
| 2012-02-14 | 2-for-1 |
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
NVO Stock Gains As UK Clears First Daily GLP-1 Weight-Loss Pill, Offsetting Security Breach News $NVO $PVAL $PPH https://stocktwits.com/news/equity/markets/nvo-stock-gains-as-uk-clears-first-daily-glp-1-weight-loss-pill-offsetting-security-breach-news/cZKTzonR72u
View on StockTwits ↗2️⃣ $PPH - VanEck Pharmaceutical ETF Carrying a substantial 22.73% allocation to $LLY. This strategy tracks the 25 largest US-listed pharmaceutical firms. While strong stock performance kept the overall price return positive, the fund did experience an organic retreat: 📈 5D Return: +0.96% 📉 Organic Growth: -6.07% 📊 Expense Ratio: 0.36%
View on StockTwits ↗One stock move can show up in very different ETF wrappers. 👉 $VFLO brings the free-cash-flow lens 👉 $PPH brings the pharma basket 👉 $DURA brings the durable-dividend angle Track daily fund flows, check portfolio exposure, and view the full holdings list on ETFDb: https://etfdb.com/tool/etf-stock-exposure-tool/ (5/5)
View on StockTwits ↗2️⃣ $PPH VanEck Pharmaceutical ETF, VanEck $PPH gives investors targeted exposure to pharma companies involved in research, development, production, marketing, and sales of pharmaceuticals. 🚀 5D Return: -3.11% 📊 $MRK Weighting: 9.593% 📈 Expense Ratio: 0.36% If $MRK is the ticker moving, $PPH is one pharma-focused basket worth checking. (3/5)
View on StockTwits ↗$SPLV $CEG $XLV $VHT $PPH While markets remain dominated by AI hype, high-growth narratives, and momentum-driven capital flows, a quieter rotation is beginning beneath the surface. Dividend ETFs—often overlooked during aggressive bull cycles—are now sitting in a rare position where many defensive income strategies have lagged despite stable fundamentals. This newsletter explores why funds like SPLV, XLV, VHT, PPH, and MORT may be entering a period where valuation compression, policy uncertainty, and interest-rate expectations create potential long-term opportunity zones for disciplined income investors. In a market obsessed with speed, the real shift may be happening in the segments that nobody is paying attention to right now. Inside the full breakdown, we dive into how healthcare uncertainty, interest-rate cycles, and defensive sector underperformance are reshaping dividend ETF valuations — and why some of the... https://www.wizeinvesting.com/p/494-in-5-years-the-long-term-energy-payoff
View on StockTwits ↗REPL, QURE Stocks Rise Amid Makary’s Reported Resignation As FDA Chief $REPL $QURE $PPH $IHE https://stocktwits.com/news/equity/markets/repl-qure-stocks-rise-amid-makary-reported-resignation-as-fda-chief/cZXXVRmReiy
View on StockTwits ↗Trump Slaps 100% Tariffs On Imported Patented Drugs, Sparing Companies That Onshore Or Cut Prices $IHE $PPH https://stocktwits.com/news/equity/markets/trump-slaps-100-percent-tariffs-on-imported-patented-drugs/cZ7U7k5RI8v
View on StockTwits ↗Trump Administration Prepares Up To 100% Pharma Tariffs On Drugs From Companies That Have Not Struck A Deal Yet: Report $SPY $DIA $PPH $IHE https://stocktwits.com/news/equity/markets/trump-new-100-pharma-tariffs-companies-no-deal-yet/cZ7xDpiRI8S
View on StockTwits ↗$PPH Share Price: $101.91 Contract Selected: Oct 16, 2026 $110 Calls Buy Zone: $2.29 – $2.84 Target Zone: $3.85 – $4.71 Potential Upside: 59% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗Novo Nordisk Receives FDA Approval For Higher Dose Of Its Weight-Loss Drug Wegovy $NVO $PPH $PVAL https://stocktwits.com/news/equity/markets/novo-nordisk-wegovy-hd-7-2-mg-approved-by-fda/cZ3aFJgRIhX
View on StockTwits ↗Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock $NVO $HIMS $PPH $PVAL $AVDE https://stocktwits.com/news/equity/markets/novo-nordisk-hims-deal-turns-wall-street-bullish-hims-stock-upgrades/cZdos7IRI7d
View on StockTwits ↗HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy $HIMS $NVO $PPH $PVAL $AVDE https://stocktwits.com/news/equity/markets/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk
View on StockTwits ↗FDA Vaccine Chief Vinay Prasad To Exit Agency In April: Report $IHE $PPH https://stocktwits.com/news/equity/markets/fda-vaccine-chief-vinay-prasad-to-exit-agency-in-april-report/cZdLgVkRI4a
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.